中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

144 records (took 0.022 seconds)

    Sodium and bicarbonate control system
    14.
    发明专利
    Sodium and bicarbonate control system 未知

    公开(公告)号：AU2018247207A1

    公开(公告)日：2019-05-23

    申请号：AU2018247207

    申请日：2018-10-09

    Applicant: MEDTRONIC INC

    Inventor： PUDIL BRYANT J ,  GERBER MARTIN T ,  HOBOT CHRISTOPHER M

    IPC: A61M1/14

    Abstract: SODIUM AND BICARBONATE CONTROL SYSTEM A sodium and bicarbonate control system, comprising: a first conductivity sensor (112) in a dialysate flow path (101); the first conductivity sensor (112) positioned downstream of a dialyzer (102) and upstream of a sorbent cartridge (107) containing urease; a water source (104) fluidly connected to the dialysate flow path (101) downstream of the first conductivity sensor (112); a bicarbonate source (109) fluidly connected to the dialysate flow path (101) downstream of the sorbent cartridge (107); a second conductivity sensor (113) in the dialysate flow path (101); the second conductivity sensor (113) positioned downstream of the bicarbonate source (109); and a processor programmed to set a water addition rate; the water addition rate set based on a sodium prescription and a conductivity measured by the first conductivity sensor (112); the processor further programmed to set a post-bicarbonate conductivity set point based on the sodium prescription and a bicarbonate prescription; the processor further programmed to control a bicarbonate addition rate to achieve the post-bicarbonate conductivity set point as measured by the second conductivity sensor (113). :112 1 1173 -1-16 118-0 11 15 116 117 108 107 yA [ Receive Sodium and Bicarbonate Prescriptions 201 Determine Pre-Sorbent And Post-Base 202 Conductivity Set Points Initiate DialysisSession J203 IMonitor Conductivity 1 And Set Water Addition 204 Rate Monitor Conductivity 205 And Set Bicarbonate Addition Rate End Dialysis Session 206

    Peritoneal dialysate purity control system
    15.
    发明专利
    Peritoneal dialysate purity control system 未知

    公开(公告)号：AU2018236807A1

    公开(公告)日：2019-04-18

    申请号：AU2018236807

    申请日：2018-09-27

    Applicant: MEDTRONIC INC

    Inventor： LURA DAVID B ,  GERBER MARTIN T ,  HOBOT CHRISTOPHER M ,  MEYER THOMAS

    IPC: A61M1/28

    Abstract: PERITONEAL DIALYSATE PURITY CONTROL SYSTEM A purity control system for use in peritoneal dialysis, the purity and control system comprising: a first fluid line fluidly connected to a peritoneal dialysate generation system and a first ultrafilter; a second fluid line fluidly connecting the first ultrafilter to a second ultrafilter; the peritoneal dialysate generation system comprising at least a water source, an osmotic agent source, an ion concentrate source, and a water purification module fluidly connected to a peritoneal dialysate generation flow path. 2105 -126 128 129 130 108 . 106 107 6 1 0 108 103 127 14 122 1 112 113 136 15121, l3134 202 03 205 206 20 208 209-| 210 211 "222 2 1 2 2 213 24 2 5 21-S2026 2 7 2 8 21 22

    Methods and compositions for treating post-operative pain comprising clonidine
    18.
    发明专利
    Methods and compositions for treating post-operative pain comprising clonidine 未知

    公开(公告)号：AU2009236157B2

    公开(公告)日：2015-05-21

    申请号：AU2009236157

    申请日：2009-04-17

    Applicant: MEDTRONIC INC ,  WARSAW ORTHOPEDIC INC

    Inventor： WOHABREBBI AMIRA ,  HOBOT CHRISTOPHER M ,  KING VANJA MARGARETA ,  CARTER TROY ,  MCKAY WILLIAM F ,  MCDONALD PHILLIP EDWARD

    IPC: A61K9/00 ,  A61K9/20 ,  A61K31/4162 ,  A61K47/34

    Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.

Patent Agency Ranking